Aesica is a leading pharmaceutical contract development and manufacturing organisation (CDMO) for both Active Pharmaceutical Ingredients (APIs) and finished dose forms.

Aesica provides a full service, end-to-end pharmaceutical development and manufacturing solution comprising capabilities in formulation development for API and finished dose, manufacturing at all scales, and packaging services. The North London, UK headquartered based company currently has approximately 1300 colleagues at five development and manufacturing sites in the UK, Germany and Italy, as well as an international office in Shanghai. As part of the Consort Medical group, Aesica's offering has expanded to include end-to-end capabilities in the design, industrialisation and manufacture of medical delivery devices, further simplifying the supply chain and increasing control for their customers.

Aesica joined Britest in 2013, recognising the fit with their own aspirations for developing and implementing new technologies and improved processes in support of business growth. Following successful demonstration of the Britest approach on a key Active Pharmaceutical Ingredient process at their Cramlington site, the company has gone on to implement the Britest approach across a range of their Zwickau, Germany and Queenborough, Kent, UK sites.